Sensient Technologies Corporation (SXT) Revenue by Segment & Business Profile
Food Pharmaceutical Colors was 36.3% of Sensient Technologies Corporation's revenue across the 5 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 5.6B
- P/E TTM
- 35.8
- Dividend yield
- 1.2%
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
What the company does
Sensient Technologies Corporation is a specialty chemicals company in the basic materials sector. In its SEC filings it reports 5 business lines: Food Pharmaceutical Colors (36%), Flavors Extracts Flavor Ingredients (32%), Agricultural Ingredients (14%), Personal Care (10%) and others. Trailing twelve-month revenue: $1.7 billion as of 2026-06-30.
Roles we read
from the filings, not the sector label- Industrial specialty chemicals
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| North America | 271M | 58.7% | +14.6% |
| Europe | 90M | 19.4% | +6.9% |
| Asia Pacific | 70M | 15.1% | +11.0% |
| All Other Segments | 31M | 6.8% | +1.8% |
Sensient Technologies Corporation — questions
- What does Sensient Technologies Corporation do?
- Sensient Technologies Corporation is a specialty chemicals company in the basic materials sector. In its SEC filings it reports 5 business lines: Food Pharmaceutical Colors (36%), Flavors Extracts Flavor Ingredients (32%), Agricultural Ingredients (14%), Personal Care (10%) and others. Trailing twelve-month revenue: $1.7 billion as of 2026-06-30.
- How does Sensient Technologies Corporation make money?
- By the lines it reports in its SEC filings: Food Pharmaceutical Colors 36.3%, Flavors Extracts Flavor Ingredients 31.7%, Agricultural Ingredients 14.4%, Personal Care 10.5%, Other 7.1% of revenue.
Every figure on this page comes from Sensient Technologies Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.